Dan Peer
Professor Tel Aviv University
Dan Peer is a Professor and Director of the Laboratory of Precision Nanomedicine and Vice President for Research at Tel Aviv University. Dan did pioneer work in developing strategies to deliver RNA payloads in a cell specific manner. He developed one of the largest lipid libraries with more than 100,000 different lipids. His lab was the first to show systemic cell specific delivery of siRNAs to immune cells. The first systemic cell specific mRNA delivery in an animal and the first to show highly efficient therapeutic genome editing in cancer in a cell type specific manner. He also developed the first extra cellular bacterial mRNA vaccine; He is the recipient of more than 40 awards and honors. He holds 148 pending and granted patents 63% of them are licensed to companies and more than 10 strategies he developed are currently in clinical testing. He is the founder of 4 startup companies (one was acquired in 2021). He has published more than 180 manuscripts; several books and gave numerous invited, plenary and keynote talks worldwide. Dan also serves as an editor and on the editorial board of more than 20 journals. Dan is an International Member of the US National Academy of Engineering and was elected in 2024 as a Fellow of the US National Academy of Inventors.
Seminars
As lipid-based nanoparticles advance beyond the liver, developers across RNA, cell, and gene industries are re-evaluating their strategies to address payload delivery challenges. This is driving new innovations, novel chemistries and methods to improve toxicity profiles, potency and efficacy, while ensuring manufacturability at scale. This interactive workshop will explore the scientific, technical, and regulatory trade-offs shaping the future of extrahepatic LNP delivery.
Join this discussion to gain key insights on:
- Exploring novel LNP and nanoparticle targeting strategies from receptor targeting, antibody conjugation and organ-selective platforms to improve biodistribution, target specificity, and improve therapeutic efficacy
- Assessing the CMC and manufacturing challenges of complex LNP formulations to ensure stability and delivery efficiency
- Delving into toxicology and pharmacology of targeting moieties, potential biological interference, and exploring practical considerations for regulatory approval of targeted LNP system
